VACBF 財務： Nykode Therapeutics ASA AI 分析

首頁

股票

VACBF

VACBF 財務

Nykode Therapeutics ASA

$0.38

22.58%

$0.07

收盤價：Feb 17, 16:00:00 GMT-5

$0.38

盤前：Feb 18, 10:21:34 GMT-5

概觀預測收益股利財務狀況

收入

資產負債表

現金流量

年度

每季

VACBF 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
營收	6	8	12	7	33	215
營收年增率 (YoY)	100%	-33%	71%	-79%	-85%	--
營收成本	--	--	--	--	--	--
毛利	--	--	--	--	--	--
銷售、一般及管理費用	17	31	28	18	17	16
研發	--	--	29	26	16	10
營業費用	33	55	69	57	41	33
其他非營業收入 (費用)	--	0	0	0	0	0
稅前淨利	-16	-45	-44	-50	-11	180
所得稅費用	-5	-6	-8	-8	-1	31
淨利	-11	-38	-35	-42	-9	149
淨利成長	-70%	9%	-17%	367%	-106%	-1,246%
稀釋後流通股數	326.54	326.54	300.52	290.11	286.34	296.14
股數年變動 (YoY)	1%	9%	4%	1%	-3%	438.99%
每股盈餘 (稀釋)	-0.03	-0.11	-0.11	-0.14	-0.03	0.5
每股盈餘成長率	-72%	2%	-21%	348%	-107%	-303%
自由現金流	-35	-51	-98	-23	0	180
每股自由現金流	--	--	--	--	--	--
毛利率	--	--	--	--	--	--
營業利益率	-433.33%	-587.5%	-466.66%	-714.28%	-21.21%	84.18%
淨利率	-183.33%	-475%	-291.66%	-600%	-27.27%	69.3%
自由現金流利潤率	-583.33%	-637.5%	-816.66%	-328.57%	0%	83.72%
EBITDA	-24	-45	-54	-49	-7	181
EBITDA 利潤率	-400%	-562.5%	-450%	-700%	-21.21%	84.18%
EBITDA 中的折舊與攤銷	2	2	2	1	0	0
EBIT	-26	-47	-56	-50	-7	181
EBIT 利潤率	-433.33%	-587.5%	-466.66%	-714.28%	-21.21%	84.18%
有效稅率	31.25%	13.33%	18.18%	16%	9.09%	17.22%

關鍵數據

前收市價

$0.31

開盤價

$0.38

當日範圍

$0.38 - $0.38

52週區間

$0.1557 - $0.38

交易量

平均成交量

166

每股盈餘 (TTM)

-0.03

股息收益率

市值

$124.0M

什麼是 NYKODE THERAPEUTICS ASA？

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 62 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

功能特性

資源